Revenue

3 Months Ended

Mar. 31, 2024

Revenue

Revenue

3.  Revenue

In connection with our acquisition of 51% ownership of PET Labs Pharmaceuticals in October 2023, we manufacture and sell nuclear medical doses for PET scanning in South Africa. For the three months ended March 31, 2024, the Company recognized revenue of $840,354. Since the acquisition did not occur until October 2023, there is no accounts receivable as of January 1, 2023 and no revenue was recognized for the three months ended March 31, 2023.

The following table presents changes in the Company’s accounts receivable for the three months ended March 31, 2024:

	Balance as of December 31, 2023		Additions		Deductions			Balance as of March 31, 2024
Accounts receivable	$	216,504	$	840,354	$	(702,775	)	$	354,083